Conversely, EHF amplifications occur in a subset of oesophageal, ovarian, stomach, bladder, and head and neck cancers, however, as discussed above, EHF is located within close proximity to ELF5 and has an amplification and deletion profile which is very similar to ELF5 (Figure 6), making it difficult to determine whether one, or perhaps both, transcription factors provides a selective advantage for these tumours. Here, ELF5 is linked to neoplasm.